See every side of every news story
Get Started
SubscribeLogin
Ukraine War
Volodymyr Zelenskyy
Donald Trump
US Politics
Hamas
Israel-Hamas Conflict
Elon Musk
US Economy
CPAC
Basketball
Baseball
Artificial Intelligence
Published • loading... • Updated

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease

Summary by Benzinga
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological-endoscopic mucosal improvement Findings to form the basis for a phase 3 program, anticipated to…

7 Articles

All
Left
3
Center
1
Right
1
BenzingaBenzinga

Press Release: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease

ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological-endoscopic mucosal improvement Findings to form the basis for a phase 3 program, anticipated to…

·New York, United States
Read Full Article
Financial PostFinancial Post

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's Disease

Teva hosting investor call Monday, February 24 at 8:00 a.m. U.S. ET

·Canada
Read Full Article
The Hamilton SpectatorThe Hamilton Spectator
+3 Reposted by 3 other sources

Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn’s Disease

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different dosesNew endpoints presented include findings on clinical and

·Hamilton, Canada
Read Full Article
stocktitan.netstocktitan.net

Can This New IBD Drug Outperform Current Treatments? Phase 2b Data Shows Remarkable 48% Remission Rate

Novel TL1A antibody demonstrates superior efficacy with up to 48% remission in UC and CD patients. Phase 3 trials planned for H2 2025.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 60% of the sources lean Left
60% Left
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

The Hamilton Spectator broke the news in Hamilton, Canada on Saturday, February 22, 2025.
Sources are mostly out of (0)

Similar News Topics

News
For You
Search
BlindspotLocal